Login to Your Account

LONDON – The era of stratified medicines that are suitable for subgroups of patients only has arrived, but there are many shortcomings to address in terms of R&D, regulation, health technology assessment, access and reimbursement, to maintain momentum and ensure the benefits are delivered.
The FDA's approval of Genzyme Corp.'s Lemtrada (alemtuzumab) for relapsing forms of multiple sclerosis (MS) Friday brought good news for patients who've had trouble with other therapies, not to mention its parent company, Sanofi SA, which received a complete response letter last year questioning the drug's benefits in light of its risks.

LONDON – The EMA is without a leader after a court ruling annulled the appointment of the executive director, Guido Rasi, three years into his five-year term.

More REGULATORY Headlines

Cast Your Vote

Has biotech’s bubble burst?: